Glioblastoma Multiforme Treatment Market Size, Share & Trends Analysis Report By Treatment (Radiation Therapy, Immunotherapy), By Drug Class, By End Use, By Region, And Segment Forecasts, 2021 - 2028
This report can be delivered to the clients within 48 Business Hours
Glioblastoma Multiforme Treatment Market Growth & Trends
The global glioblastoma multiforme treatment market size is expected to reach USD 4.2 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.8% from 2021 to 2028. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.
In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.
Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company’s Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.
Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.
Various initiatives undertaken by the governments and non-government bodies across the globe to increase awareness by educating people living with glioblastoma multiforme and raising funds for R&D activities and treatment are expected to fuel the glioblastoma multiforme (GBM) treatment market growth during the forecast period. For instance, Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps in raising awareness about glioblastoma multiforme and motivating people to donate money for glioblastoma multiforme research activities.
Organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The main aim of the campaign is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Moreover, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month.
Glioblastoma Multiforme Treatment Market Report Highlights
Glioblastoma Multiforme Treatment Market Growth & Trends
The global glioblastoma multiforme treatment market size is expected to reach USD 4.2 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 8.8% from 2021 to 2028. The market is driven by the rising prevalence of the disease and increasing approval for novel therapy and combination therapy.
In recent years, the industry has been growing rapidly owing to the introduction of innovative products and rising interest of major pharmaceutical companies in the market due to favorable guidelines and rising incidence of the disease. For instance, companies such as Bristol Myers Squibb; CNS Pharmaceuticals, Inc.; and Bayer have novel products in the pipeline for glioblastoma multiforme. These products are likely to boost competitive rivalry in the market in the coming years.
Moreover, companies are collaborating to develop novel treatments. For instance, in October 2019, Advaxis, Inc., a clinical-stage biotechnology company, announced a research collaboration agreement with the University of California for the development and commercialization of novel immunotherapy by using the company’s Lm Technology in mouse tumor models of glioblastoma multiforme. An increase in collaborations between researchers and market players is expected to boost the development of novel and effective treatment options for glioblastoma multiforme.
Existing companies are willing to acquire new companies with pipeline products to diversify their product portfolio. For instance, in May 2019, Merck announced the upfront USD 1.1 billion acquisition of Peloton Therapeutics, which grants it access to the PT2977 under trial glioblastoma drug. This acquisition is likely to strengthen its pipeline and improve its future revenue-generation ability.
Various initiatives undertaken by the governments and non-government bodies across the globe to increase awareness by educating people living with glioblastoma multiforme and raising funds for R&D activities and treatment are expected to fuel the glioblastoma multiforme (GBM) treatment market growth during the forecast period. For instance, Ping Mobile, a mobile messaging platform, has launched a mobile campaign to increase awareness about brain cancer. This helps in raising awareness about glioblastoma multiforme and motivating people to donate money for glioblastoma multiforme research activities.
Organizations such as the National Brain Tumor Society, Brain Tumour Foundation of Canada, and Cure Brain Cancer Foundation are also involved in many awareness campaigns to raise awareness among people about the condition. In the U.K., March is Brain Tumor Awareness month, a campaign established by member charities of Brain Tumor Research. The main aim of the campaign is to spread awareness about the lack of funding for brain tumor research, and it helps people understand brain tumors and their treatment. Moreover, Novocure undertook many activities to spread awareness about glioblastoma multiforme during Brain Tumor Awareness Month.
Glioblastoma Multiforme Treatment Market Report Highlights
- Based on treatment, in 2020, radiation therapy held the largest share owing to various benefits associated with it such as improved survival rate and effectiveness
- By drug class, the others segment led the market in 2020 owing to the high number of prescriptions. The segment includes everolimus, corticosteroids, and 5-aminolevulinic acid (5-ALA)
- The hospitals end-use segment dominated the market in 2020 and the trend is expected to continue during the forecast period. Hospitals are preferred by patients in terms of treatment accessibility and convenience
- Asia Pacific is projected to witness the fastest growth during the forecast period owing to the presence of large unmet needs in the market and the growing awareness about glioblastoma multiforme
- North America dominated the market in 2020 due to favorable reimbursement policies and the presence of major players in the region
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing incidence of glioblastoma multiforme
3.3.1.2 Increasing approval for glioblastoma multiforme treatment
3.3.1.3 Increasing R&D activities
3.3.1.4 Rising awareness about glioblastoma multiforme
3.3.2 Market Restraint Analysis
3.3.2.1 Lack of effective therapies for glioblastoma multiforme
3.3.2.2 HIgh cost of drug development and stringent regulations
3.4 Market Analysis Tools
3.4.1 Industry Analysis: Porter’s
3.4.2 PESTLE Analysis
3.5 Regulatory & Reimbursement Scenario
3.5.1 Pipeline Analysis
3.5.2 Epidemiology Analysis by Region
CHAPTER 4 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: SEGMENT ANALYSIS, BY TREATMENT, 2017 - 2028 (USD MILLION)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2020 & 2028
4.3 Segment Market Dashboard
4.4 Global Glioblastoma Multiforme Treatment Market, by treatment, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.6 Surgery
4.6.1 Surgery market estimates and forecast, 2017 - 2028 (USD Million)
4.7 Radiation Therapy
4.7.1 Radiation therapy market estimates and forecast, 2017 - 2028 (USD Million)
4.8 Chemotherapy
4.8.1 Chemotherapy market estimates and forecast, 2017 - 2028 (USD million)
4.9 Targeted Therapy
4.9.1 Targeted therapy market estimates and forecast, 2017 - 2028 (USD million)
4.10 Tumor Treating Fields Therapy
4.10.1 Tumor Treating fields therapy market estimates and forecast, 2017 - 2028 (USD million)
4.11 Immunotherapy
4.11.1 Immunotherapy market estimates and forecast, 2017 - 2028 (USD million)
CHAPTER 5 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: SEGMENT ANALYSIS, BY DRUG CLASS, 2017 - 2028 (USD MILLION)
5.1 Definition and Scope
5.2 Drug Class Market Share Analysis, 2020 & 2028
5.3 Segment Market Dashboard
5.4 Global Glioblastoma Multiforme Treatment Market, by Drug Class, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.6 Temozolomide
5.6.1 Temozolomide market estimates and forecast, 2017 - 2028 (USD Million)
5.7 Bevacizumab
5.7.1 Bevacizumab market estimates and forecast, 2017 - 2028 (USD Million)
5.8 Lomustine
5.8.1 Lomustine market estimates and forecast, 2017 - 2028 (USD million)
5.9 Carmustine Wafers
5.9.1 Carmustine wafers market estimates and forecast, 2017 - 2028 (USD million)
5.10 Others
5.10.1 Others market estimates and forecast, 2017 - 2028 (USD million)
CHAPTER 6 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: SEGMENT ANALYSIS, BY END-USE, 2017 - 2028 (USD MILLION)
6.1 Definition and Scope
6.2 End-use Market Share Analysis, 2020 & 2028
6.3 Segment Market Dashboard
6.4 Global Glioblastoma Multiforme Treatment Market, by End-Use, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.6 Hospitals
6.6.1 Hospitals market estimates and forecast, 2017 - 2028 (USD Million)
6.7 Clinics
6.7.1 Clinics market estimates and forecast, 2017 - 2028 (USD Million)
6.8 Ambulatory Surgical Centers
6.8.1 Ambulatory surgical centers market estimates and forecast, 2017 - 2028 (USD million)
CHAPTER 7 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: REGIONAL MARKET ANALYSIS, 2017 - 2028 (USD MILLION)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020 & 2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Market Size, & Forecasts, Trend Analysis, 2020 to 2028
7.6 North America
7.6.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
7.6.2 U.S.
7.6.2.1 U.S. Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.6.3 Canada
7.6.3.1 Canada Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7 Europe
7.7.1 Europe Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.2 U.K.
7.7.2.1 U.K. Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.3 Germany
7.7.3.1 Germany Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.4 Spain
7.7.4.1 Spain Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.5 France
7.7.5.1 France Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.6 Italy
7.7.6.1 Italy Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.7 Russia
7.7.7.1 Russia Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8 Asia Pacific
7.8.1 Asia Pacific Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.2 Japan
7.8.2.1 Japan Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.3 China
7.8.3.1 China Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.4 India
7.8.4.1 India Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.5 South Korea
7.8.5.1 South Korea Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.6 Australia
7.8.6.1 Australia Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.7 Singapore
7.8.7.1 Singapore Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9 Latin America
7.9.1 Latin America Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9.2 Brazil
7.9.2.1 Brazil Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9.3 Mexico
7.9.3.1 Mexico Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9.4 Argentina
7.9.4.1 Argentina Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10 MEA
7.10.1 MEA Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10.2 South Africa
7.10.2.1 South Africa Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10.3 Saudi Arabia
7.10.3.1 Saudi Arabia Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10.4 UAE
7.10.4.1 UAE Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
CHAPTER 8 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: COMPETITIVE ANALYSIS
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.2 Company Categorization
8.2.1 Innovators
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.4 Public Companies
8.4.1 Company Market position analysis
8.4.2 Competitive Dashboard Analysis
8.4.2.1 Market Differentiators
8.5 Private Companies
8.5.1 List of key emerging companies
8.5.2 Heat Map Analysis
8.6 Major Deals and Strategic Alliances Analysis
8.6.1 Joint Ventures
8.6.2 Acquisitions
8.6.3 Licensing and Partnerships
8.6.4 Technological Collaborations
8.7 Company Profiles
8.7.1 Merck & Co., Inc.
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.2 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Teva Pharmaceutical Industries Ltd.
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 Sun Pharmaceutical Industries Ltd.
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 F. Hoffmann-La Roche Ltd.
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Pfizer, Inc.
8.7.6.1 Company overview
8.7.6.2 Financial performance
8.7.6.3 Product benchmarking
8.7.6.4 Strategic initiatives
8.7.7 Amgen, Inc.
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.7.4 Strategic initiatives
8.7.8 Arbor Pharmaceuticals, LLC
8.7.8.1 Company overview
8.7.8.2 Product benchmarking
8.7.8.3 Strategic initiatives
8.7.9 Amneal Pharmaceuticals
8.7.9.1 Company overview
8.7.9.2 Financial performance
8.7.9.3 Product benchmarking
8.7.9.4 Strategic initiatives
8.7.10 Karyopharm Therapeutics, Inc.
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
1.1 Market Segmentation and Scope
1.1.1 Regional scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective
1.10.2 Objective
1.10.3 Objective
1.10.4 Objective
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET VARIABLES, TRENDS, AND SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Increasing incidence of glioblastoma multiforme
3.3.1.2 Increasing approval for glioblastoma multiforme treatment
3.3.1.3 Increasing R&D activities
3.3.1.4 Rising awareness about glioblastoma multiforme
3.3.2 Market Restraint Analysis
3.3.2.1 Lack of effective therapies for glioblastoma multiforme
3.3.2.2 HIgh cost of drug development and stringent regulations
3.4 Market Analysis Tools
3.4.1 Industry Analysis: Porter’s
3.4.2 PESTLE Analysis
3.5 Regulatory & Reimbursement Scenario
3.5.1 Pipeline Analysis
3.5.2 Epidemiology Analysis by Region
CHAPTER 4 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: SEGMENT ANALYSIS, BY TREATMENT, 2017 - 2028 (USD MILLION)
4.1 Definition and Scope
4.2 Treatment Market Share Analysis, 2020 & 2028
4.3 Segment Market Dashboard
4.4 Global Glioblastoma Multiforme Treatment Market, by treatment, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.6 Surgery
4.6.1 Surgery market estimates and forecast, 2017 - 2028 (USD Million)
4.7 Radiation Therapy
4.7.1 Radiation therapy market estimates and forecast, 2017 - 2028 (USD Million)
4.8 Chemotherapy
4.8.1 Chemotherapy market estimates and forecast, 2017 - 2028 (USD million)
4.9 Targeted Therapy
4.9.1 Targeted therapy market estimates and forecast, 2017 - 2028 (USD million)
4.10 Tumor Treating Fields Therapy
4.10.1 Tumor Treating fields therapy market estimates and forecast, 2017 - 2028 (USD million)
4.11 Immunotherapy
4.11.1 Immunotherapy market estimates and forecast, 2017 - 2028 (USD million)
CHAPTER 5 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: SEGMENT ANALYSIS, BY DRUG CLASS, 2017 - 2028 (USD MILLION)
5.1 Definition and Scope
5.2 Drug Class Market Share Analysis, 2020 & 2028
5.3 Segment Market Dashboard
5.4 Global Glioblastoma Multiforme Treatment Market, by Drug Class, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.6 Temozolomide
5.6.1 Temozolomide market estimates and forecast, 2017 - 2028 (USD Million)
5.7 Bevacizumab
5.7.1 Bevacizumab market estimates and forecast, 2017 - 2028 (USD Million)
5.8 Lomustine
5.8.1 Lomustine market estimates and forecast, 2017 - 2028 (USD million)
5.9 Carmustine Wafers
5.9.1 Carmustine wafers market estimates and forecast, 2017 - 2028 (USD million)
5.10 Others
5.10.1 Others market estimates and forecast, 2017 - 2028 (USD million)
CHAPTER 6 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: SEGMENT ANALYSIS, BY END-USE, 2017 - 2028 (USD MILLION)
6.1 Definition and Scope
6.2 End-use Market Share Analysis, 2020 & 2028
6.3 Segment Market Dashboard
6.4 Global Glioblastoma Multiforme Treatment Market, by End-Use, 2017 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.6 Hospitals
6.6.1 Hospitals market estimates and forecast, 2017 - 2028 (USD Million)
6.7 Clinics
6.7.1 Clinics market estimates and forecast, 2017 - 2028 (USD Million)
6.8 Ambulatory Surgical Centers
6.8.1 Ambulatory surgical centers market estimates and forecast, 2017 - 2028 (USD million)
CHAPTER 7 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: REGIONAL MARKET ANALYSIS, 2017 - 2028 (USD MILLION)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020 & 2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Market Size, & Forecasts, Trend Analysis, 2020 to 2028
7.6 North America
7.6.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
7.6.2 U.S.
7.6.2.1 U.S. Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.6.3 Canada
7.6.3.1 Canada Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7 Europe
7.7.1 Europe Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.2 U.K.
7.7.2.1 U.K. Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.3 Germany
7.7.3.1 Germany Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.4 Spain
7.7.4.1 Spain Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.5 France
7.7.5.1 France Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.6 Italy
7.7.6.1 Italy Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.7.7 Russia
7.7.7.1 Russia Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8 Asia Pacific
7.8.1 Asia Pacific Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.2 Japan
7.8.2.1 Japan Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.3 China
7.8.3.1 China Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.4 India
7.8.4.1 India Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.5 South Korea
7.8.5.1 South Korea Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.6 Australia
7.8.6.1 Australia Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.8.7 Singapore
7.8.7.1 Singapore Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9 Latin America
7.9.1 Latin America Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9.2 Brazil
7.9.2.1 Brazil Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9.3 Mexico
7.9.3.1 Mexico Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.9.4 Argentina
7.9.4.1 Argentina Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10 MEA
7.10.1 MEA Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10.2 South Africa
7.10.2.1 South Africa Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10.3 Saudi Arabia
7.10.3.1 Saudi Arabia Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
7.10.4 UAE
7.10.4.1 UAE Glioblastoma Multiforme Treatment Market, 2017 - 2028 (USD Million)
CHAPTER 8 GLIOBLASTOMA MULTIFORME (GBM) TREATMENT MARKET: COMPETITIVE ANALYSIS
8.1 Recent Developments & Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix
8.2 Company Categorization
8.2.1 Innovators
8.3 Vendor Landscape
8.3.1 List of key distributors and channel partners
8.3.2 Key customers
8.4 Public Companies
8.4.1 Company Market position analysis
8.4.2 Competitive Dashboard Analysis
8.4.2.1 Market Differentiators
8.5 Private Companies
8.5.1 List of key emerging companies
8.5.2 Heat Map Analysis
8.6 Major Deals and Strategic Alliances Analysis
8.6.1 Joint Ventures
8.6.2 Acquisitions
8.6.3 Licensing and Partnerships
8.6.4 Technological Collaborations
8.7 Company Profiles
8.7.1 Merck & Co., Inc.
8.7.1.1 Company overview
8.7.1.2 Financial performance
8.7.1.3 Product benchmarking
8.7.1.4 Strategic initiatives
8.7.2 Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)
8.7.2.1 Company overview
8.7.2.2 Financial performance
8.7.2.2 Product benchmarking
8.7.2.4 Strategic initiatives
8.7.3 Teva Pharmaceutical Industries Ltd.
8.7.3.1 Company overview
8.7.3.2 Financial performance
8.7.3.3 Product benchmarking
8.7.3.4 Strategic initiatives
8.7.4 Sun Pharmaceutical Industries Ltd.
8.7.4.1 Company overview
8.7.4.2 Financial performance
8.7.4.3 Product benchmarking
8.7.4.4 Strategic initiatives
8.7.5 F. Hoffmann-La Roche Ltd.
8.7.5.1 Company overview
8.7.5.2 Financial performance
8.7.5.3 Product benchmarking
8.7.5.4 Strategic initiatives
8.7.6 Pfizer, Inc.
8.7.6.1 Company overview
8.7.6.2 Financial performance
8.7.6.3 Product benchmarking
8.7.6.4 Strategic initiatives
8.7.7 Amgen, Inc.
8.7.7.1 Company overview
8.7.7.2 Financial performance
8.7.7.3 Product benchmarking
8.7.7.4 Strategic initiatives
8.7.8 Arbor Pharmaceuticals, LLC
8.7.8.1 Company overview
8.7.8.2 Product benchmarking
8.7.8.3 Strategic initiatives
8.7.9 Amneal Pharmaceuticals
8.7.9.1 Company overview
8.7.9.2 Financial performance
8.7.9.3 Product benchmarking
8.7.9.4 Strategic initiatives
8.7.10 Karyopharm Therapeutics, Inc.
8.7.10.1 Company overview
8.7.10.2 Financial performance
8.7.10.3 Product benchmarking
8.7.10.4 Strategic initiatives
LIST OF TABLES
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of GBM
Table 4 North America GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 5 North America GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 6 North America GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 7 North America GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 9 U.S. GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 10 U.S. GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 11 U.S. GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 12 Canada GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 13 Canada GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 14 Canada GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 15 Europe GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 16 Europe GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 17 Europe GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 18 Europe GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 19 U.K. GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 20 U.K. GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 21 U.K. GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 22 Germany GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 23 Germany GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 24 Germany GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 25 Italy GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 26 Italy GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 27 Italy GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 28 France GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 29 France GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 30 France GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 31 Spain GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 32 Spain GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 33 Spain GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 34 Russia GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 35 Russia GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 36 Russia GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 37 Asia Pacific GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 38 Asia Pacific GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 39 Asia Pacific GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 40 Asia Pacific GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 41 Japan GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 42 Japan GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 43 Japan GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 44 China GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 45 China GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 46 China GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 47 India GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 48 India GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 49 India GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 50 South Korea GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 51 South Korea GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 52 South Korea GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 53 Australia GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 54 Australia GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 55 Australia GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 56 Singapore GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 57 Singapore GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 58 Singapore GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 59 Latin America GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 60 Latin America GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 61 Latin America GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 62 Latin America GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 63 Brazil GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 64 Brazil GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 65 Brazil GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 66 Mexico GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 67 Mexico GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 68 Mexico GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 69 Argentina GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 70 Argentina GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 71 Argentina GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 72 MEA GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 73 MEA GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 74 MEA GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 75 MEA GBM Treatment Market, By End Use, 2017 - 2028 (USD Million))
Table 76 South Africa GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 77 South Africa GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 78 South Africa GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 79 Saudi Arabia GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 80 Saudi Arabia GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 81 Saudi Arabia GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 82 UAE GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 83 UAE GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 84 UAE GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Incidence of GBM
Table 4 North America GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 5 North America GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 6 North America GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 7 North America GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 9 U.S. GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 10 U.S. GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 11 U.S. GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 12 Canada GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 13 Canada GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 14 Canada GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 15 Europe GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 16 Europe GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 17 Europe GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 18 Europe GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 19 U.K. GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 20 U.K. GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 21 U.K. GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 22 Germany GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 23 Germany GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 24 Germany GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 25 Italy GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 26 Italy GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 27 Italy GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 28 France GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 29 France GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 30 France GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 31 Spain GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 32 Spain GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 33 Spain GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 34 Russia GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 35 Russia GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 36 Russia GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 37 Asia Pacific GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 38 Asia Pacific GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 39 Asia Pacific GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 40 Asia Pacific GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 41 Japan GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 42 Japan GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 43 Japan GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 44 China GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 45 China GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 46 China GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 47 India GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 48 India GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 49 India GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 50 South Korea GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 51 South Korea GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 52 South Korea GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 53 Australia GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 54 Australia GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 55 Australia GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 56 Singapore GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 57 Singapore GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 58 Singapore GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 59 Latin America GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 60 Latin America GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 61 Latin America GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 62 Latin America GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 63 Brazil GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 64 Brazil GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 65 Brazil GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 66 Mexico GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 67 Mexico GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 68 Mexico GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 69 Argentina GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 70 Argentina GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 71 Argentina GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 72 MEA GBM Treatment Market, By Country, 2017 - 2028 (USD Million)
Table 73 MEA GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 74 MEA GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 75 MEA GBM Treatment Market, By End Use, 2017 - 2028 (USD Million))
Table 76 South Africa GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 77 South Africa GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 78 South Africa GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 79 Saudi Arabia GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 80 Saudi Arabia GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 81 Saudi Arabia GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
Table 82 UAE GBM Treatment Market, By Treatment, 2017 - 2028 (USD Million)
Table 83 UAE GBM Treatment Market, By Drug Class, 2017 - 2028 (USD Million)
Table 84 UAE GBM Treatment Market, By End Use, 2017 - 2028 (USD Million)
LIST OF FIGURES
Fig. 1 Glioblastoma multiforme treatment market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Glioblastoma multiforme treatment market outlook (2020)
Fig. 9 Penetration & growth prospect mapping
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Porter’s five forces analysis
Fig. 13 PESTLE analysis
Fig. 14 Glioblastoma multiforme treatment market: Treatment movement analysis
Fig. 15 Segment Market Dashboard
Fig. 16 Glioblastoma multiforme treatment market treatment outlook: Key takeaways
Fig. 17 Surgery market estimates and forecast, 2017 - 2028 (USD million)
Fig. 18 Radiation therapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 19 Chemotherapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 20 Targeted therapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 21 Tumor treating fields therapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 22 Immunotherapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 23 Glioblastoma multiforme treatment market: Drug class movement analysis
Fig. 24 Segment Market Dashboard
Fig. 25 Glioblastoma multiforme treatment market drug class outlook: Key takeaways
Fig. 26 Temozolomide market estimates and forecast, 2017 - 2028 (USD million)
Fig. 27 Bevacizumab market estimates and forecast, 2017 - 2028 (USD million)
Fig. 28 Lomustine market estimates and forecast, 2017 - 2028 (USD million)
Fig. 29 Carmustine wafers market estimates and forecast, 2017 - 2028 (USD million)
Fig. 30 Others market estimates and forecast, 2017 - 2028 (USD million)
Fig. 31 Glioblastoma multiforme treatment market: End-use movement analysis
Fig. 32 Segment Market Dashboard
Fig. 33 Glioblastoma multiforme treatment market end-use outlook: Key takeaways
Fig. 34 Hospitals market estimates and forecast, 2017 - 2028 (USD million)
Fig. 35 Clinics market estimates and forecast, 2017 - 2028 (USD million)
Fig. 36 Ambulatory surgical centers market estimates and forecast, 2017 - 2028 (USD million)
Fig. 37 Regional outlook, 2020 & 2028
Fig. 38 Regional Market Dashboard
Fig. 39 Regional market place: Key takeaways
Fig. 40 North America
Fig. 41 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 42 U.S.
Fig. 43 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 44 Canada
Fig. 45 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 46 Europe
Fig. 47 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 48 U.K.
Fig. 49 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 50 Germany
Fig. 51 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 52 Spain
Fig. 53 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 54 France
Fig. 55 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 56 Italy
Fig. 57 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 58 Russia
Fig. 59 Russia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 60 Asia Pacific
Fig. 61 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 62 Japan
Fig. 63 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 64 China
Fig. 65 China market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 66 India
Fig. 67 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 68 South Korea
Fig. 69 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 70 Australia
Fig. 71 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 72 Singapore
Fig. 73 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 74 Latin America
Fig. 75 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 76 Brazil
Fig. 77 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 78 Mexico
Fig. 79 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 80 Argentina
Fig. 81 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 82 MEA
Fig. 83 MEA market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 84 South Africa
Fig. 85 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 86 Saudi Arabia
Fig. 87 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 88 UAE
Fig. 89 UAE market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 90 Ansoff Matrix
Fig. 91 Company market position analysis
Fig. 92 Company market position analysis
Fig. 93 Market differentiators
Fig. 94 Heat Map Analysis
Fig. 1 Glioblastoma multiforme treatment market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Glioblastoma multiforme treatment market outlook (2020)
Fig. 9 Penetration & growth prospect mapping
Fig. 10 Market driver relevance analysis (Current & future impact)
Fig. 11 Market restraint relevance analysis (Current & future impact)
Fig. 12 Porter’s five forces analysis
Fig. 13 PESTLE analysis
Fig. 14 Glioblastoma multiforme treatment market: Treatment movement analysis
Fig. 15 Segment Market Dashboard
Fig. 16 Glioblastoma multiforme treatment market treatment outlook: Key takeaways
Fig. 17 Surgery market estimates and forecast, 2017 - 2028 (USD million)
Fig. 18 Radiation therapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 19 Chemotherapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 20 Targeted therapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 21 Tumor treating fields therapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 22 Immunotherapy market estimates and forecast, 2017 - 2028 (USD million)
Fig. 23 Glioblastoma multiforme treatment market: Drug class movement analysis
Fig. 24 Segment Market Dashboard
Fig. 25 Glioblastoma multiforme treatment market drug class outlook: Key takeaways
Fig. 26 Temozolomide market estimates and forecast, 2017 - 2028 (USD million)
Fig. 27 Bevacizumab market estimates and forecast, 2017 - 2028 (USD million)
Fig. 28 Lomustine market estimates and forecast, 2017 - 2028 (USD million)
Fig. 29 Carmustine wafers market estimates and forecast, 2017 - 2028 (USD million)
Fig. 30 Others market estimates and forecast, 2017 - 2028 (USD million)
Fig. 31 Glioblastoma multiforme treatment market: End-use movement analysis
Fig. 32 Segment Market Dashboard
Fig. 33 Glioblastoma multiforme treatment market end-use outlook: Key takeaways
Fig. 34 Hospitals market estimates and forecast, 2017 - 2028 (USD million)
Fig. 35 Clinics market estimates and forecast, 2017 - 2028 (USD million)
Fig. 36 Ambulatory surgical centers market estimates and forecast, 2017 - 2028 (USD million)
Fig. 37 Regional outlook, 2020 & 2028
Fig. 38 Regional Market Dashboard
Fig. 39 Regional market place: Key takeaways
Fig. 40 North America
Fig. 41 North America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 42 U.S.
Fig. 43 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 44 Canada
Fig. 45 Canada market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 46 Europe
Fig. 47 Europe market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 48 U.K.
Fig. 49 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 50 Germany
Fig. 51 Germany market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 52 Spain
Fig. 53 Spain market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 54 France
Fig. 55 France market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 56 Italy
Fig. 57 Italy market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 58 Russia
Fig. 59 Russia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 60 Asia Pacific
Fig. 61 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 62 Japan
Fig. 63 Japan market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 64 China
Fig. 65 China market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 66 India
Fig. 67 India market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 68 South Korea
Fig. 69 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 70 Australia
Fig. 71 Australia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 72 Singapore
Fig. 73 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 74 Latin America
Fig. 75 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 76 Brazil
Fig. 77 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 78 Mexico
Fig. 79 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 80 Argentina
Fig. 81 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 82 MEA
Fig. 83 MEA market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 84 South Africa
Fig. 85 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 86 Saudi Arabia
Fig. 87 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 88 UAE
Fig. 89 UAE market estimates and forecast, 2017 - 2028 (USD Million)
Fig. 90 Ansoff Matrix
Fig. 91 Company market position analysis
Fig. 92 Company market position analysis
Fig. 93 Market differentiators
Fig. 94 Heat Map Analysis
